The effects of normoxic endurance exercise on erythropoietin (EPO) production and the impact of selective β₁ and non-selective β₁ β₂ adrenergic receptor blockade.

Azadan, Rod J.; Agha, Nadia H.; Kunz, Hawley E.; Baker, Forrest L.; Mylabathula, Preteesh L.; Ledoux, Tracy A.; O'Connor, Daniel P.; Pedlar, Charles R.; Simpson, Richard J.

<bold>Purpose: </bold>Habitual endurance exercise results in increased erythropoiesis, which is primarily controlled by erythropoietin (EPO), yet studies demonstrating upregulation of EPO via a single bout of endurance exercise have been equivocal. This study compares the acute EPO response to 30 min of high versus 90 min of moderate-intensity endurance exercise and whether that response can be upregulated via selective adrenergic receptor blockade.<bold>Methods: </bold>Using a counterbalanced, cross-over design, fifteen participants (age 28 ± 8) completed two bouts of running (30-min, high intensity vs 90-min, moderate intensity) matched for overall training stress. A separate cohort of fourteen participants (age 31 ± 6) completed three bouts of 30-min high-intensity cycling after ingesting the preferential β1-adrenergic receptor (AR) antagonist bisoprolol, the non-preferential β1 + β2 antagonist nadolol or placebo. Venous blood was collected before, during, and after exercise, and serum EPO levels were determined by ELISA.<bold>Results: </bold>No detectable EPO response was observed during or after high intensity running, however, in the moderate-intensity trial EPO was significantly elevated at both during-exercise timepoints (+ 6.8% ± 2.3% at 15 min and + 8.7% ± 2.2% at 60 min). No significant change in EPO was observed post-cycling or between the trials involving βAR blockade.<bold>Conclusion: </bold>Neither training mode (running or cycling), nor beta-blockade significantly influenced the EPO response to 30 min of high-intensity exercise, however, 90 min of moderate-intensity running elevated EPO during exercise, returning to baseline immediately post-exercise. Identifying the optimal mode, duration and intensity required to evoke an EPO response to exercise may help tailor exercise prescriptions designed to maximize EPO response for both performance and clinical applications.

ADRENERGIC receptors; ERYTHROPOIETIN; COOLDOWN; ERYTHROPOIESIS; BIOCHEMISTRY; NADOLOL; RUNNING; PHYSICAL fitness; ADRENERGIC beta blockers; CARDIOVASCULAR agents; CYCLING; PHENOMENOLOGY; RANDOMIZED controlled trials; RESEARCH funding; CROSSOVER trials; PHARMACODYNAMICS

European Journal of Applied Physiology, 2021, Vol 121, Issue 5, p1499

1439-6319

Academic Journal

10.1007/s00421-020-04558-4